Zacks Research Issues Pessimistic Forecast for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at Zacks Research reduced their Q1 2025 EPS estimates for Charles River Laboratories International in a research note issued to investors on Wednesday, March 12th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.08 per share for the quarter, down from their prior estimate of $3.10. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.

Several other equities research analysts have also issued reports on CRL. Bank of America lowered their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. UBS Group restated a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $191.31.

Charles River Laboratories International Trading Up 1.1 %

Shares of CRL stock opened at $177.02 on Monday. Charles River Laboratories International has a 1 year low of $150.79 and a 1 year high of $274.77. The firm’s fifty day simple moving average is $167.21 and its 200 day simple moving average is $184.18. The firm has a market capitalization of $9.05 billion, a P/E ratio of 1,180.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year.

Insider Buying and Selling

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CRL. Virtu Financial LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $601,000. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares during the last quarter. State Street Corp increased its stake in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock valued at $22,060,000 after acquiring an additional 3,714 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).